A Double Blind Placebo Controlled Trial of Daunomycin and Cytosine Arabinoside With or Without rhG-CSF in Elderly Patients With Acute Myeloid Leukemia
Publication Information Expand/Collapse
PMid: PMID30315233 | PMC number: PMC6367002
PMid: PMID29370458 | PMC number: PMC5963502
PMid: PMID29172682 | PMC number: PMC5808392
PMid: PMID27986655 | PMC number: PMC5370550
PMid: PMID28222251; PMC5705230
PMid: PMID27055872 | PMC number: PMC4980556
Prognostic significance of NPM1 mutations in the absence of FLT3-Internal Tandem Duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report
PMid: PMID25713434 | PMC number: PMC437285
PMid: PMID25884949 | PMC number: PMCID4401549
PMid: PMID25113226 | PMC number: PMC4318722
PMid: PMID25527568 | PMC number: PMC4349271
PMid: PMID24383844 | PMC number: PMC4117470
PMid: PMID23760400 | PMC number: PMC4457325
PMid: PMID24627276 | PMC number: PMC3982777
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
PMid: PMID23967110 | PMC number: PMC3743845
PMid: PMID22722750 | PMC number: PMC4457316
PMid: PMID23325837 | PMC number: PMC3612855
PMid: PMID23829510 | PMC number: PMC4128010
Impact of cytarabine dose in the induction regimen on the outcome of patients with newly diagnosed acute myeloid leukemia with or without NPM1 and/or FLT3 mutations: A SWOG and MD Anderson Cancer Center Report
PMid: PMID21928314 | PMC number: PMC3490403
PMid: PMID22315487 | PMC number: PMCID3436242
Single-cell network profiling (SCNP)-based classifier to predict response to induction therapy in elderlly patients with acute myeloid leukemia (AML): validation in two independent sample sets from ECOG and SWOG trials
Expression of topoisomerase II isoforms a and B in adult patients with acute myeloid leukemia (AML): relationship to immunophenotype and treatment outcome
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype [PMID21330329; PMC3069244]
Cytarabine dose for acute myeloid leukemia. (Letter to the Editor) [PMID21631340]
KIT mutations are very uncommon among elderly AML patients: a SWOG report
DNMT3A mutations independently predict poor outcome in older AML patients: a SWOG report
Prognostic import of French-American-British (FAB) system as embedded in 2008 revision of World Health Organization classification of AML
Prevalence and clinical implications of IDH1 R140 and R172 mutations in older adults with AML: a report from SWOG
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a Children's Oncology Group and Southwest Oncology Group Study [PMID21873548; PMC3208275]
Prediction of early death following induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
PMid: PMID21969499 | PMC number: PMC3221524
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study[PMID20376086; PMC2944692]
The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study
PMid: PMID20562328 | PMC number: PMC3709629
Over-expression of novel IRF8 splice variants is associated with a significant decrease in relapse-free survival in adult AML patients
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a Children's Oncology Group and Southwest Oncology Group Study
Influence of residual normal metaphases in patients with monosomal karyotype
Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia [PMC2630271; PMID18927435]
Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328
Minority report: how best to analyze clinical trial data to address disparities
Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML? [PMID18342809]
Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials [PMID17197435]
Age and acute myeloid leukemia
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials.
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukemia
Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group Clinical Trial
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
The significance of trisomy 8 in myeloid leukemia: a Southwest Oncology Group (SWOG) study.
Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sevsitive and specific.
Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia
Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia
Acute myelogenous leukemia and aging. Clinical interactions.
Microsatellite Instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature
24-color karyotyping (multiplex or M-fish) reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031).
AML in the elderly: a biologically distinct disease in which MDR1 expression and unfavorable cytogenetics contribute to poor clinical response. Studies of the Southwest Oncology Group.
Biological features of acute myeloid leukemia in the elderly.
Economic analysis of granulocyte colony stimulating factor (G-CSF) as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group (SWOG) clinical trial.
Cell cycle arrest and therapeutic sensitivity in de novo AML.
Development of a highly sensitive multiparameter flow cytometric assay correlating MDR1 expression and function: Clinical application to acute myeloid leukemia.
Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Frequency and clinical significance of expression of the multidrug resistance proteins, MDR1, MRP1 and LRP in acute myeloid leukemia patients less than 65 years old. A Southwest Oncology Group study.
Trisomy 10 as the sole cytogenetic abnormality in hematologic neoplasia.
AML in the elderly: Stratification by MDR1 phenotype, secondary vs de novo status, and cytogenetics identifies patients with high complete remission (CR) rates. A Southwest Oncology Group study.
Cytogenetics, MDR1, and disease status in elderly AML identify a subgroup with a high complete remission (CR) rate: A Southwest Oncology Group study.
Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations.
Acute myeloid leukemia in the elderly: high frequency of trilineage dyspoiesis suggests that elderly AML is biologically similar to AML arising secondary to myelodysplasia.
Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1).
A subgroup of elderly AML patients with a high complete remission rate can be defined.
Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases
Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine wiht our without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group Study.
Genetic heterogeneity of acute myeloid leukemia (AML) with FAB-AML M3 morphology
Heterogeneity in CBFB/MYH11 fusion messages encoded by inv(16) and t(16;16) in acute myelogenous leukemia (AML)
Amplification of the E2F-1 transcription factor gene in the HEL erythroleukemia cell line
Heterogeneity in CBF'/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia
Trisomy 11: an association with stem/progenitor cell immunophenotype.
MDR1 expression is highly predictive for achievement of complete remission (CR) in acute myeloid leukemia (AML) in the elderly: A Southwest Oncology Group study.
CD56: A determinant of extramedullary and central nervous system (CNS) involvement in acute myeloid leukemia (AML). Modern Pathology 7(1):120A (#695)
HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3
Trisomy 8: A primary cytogenetic anomaly in leukemia?
Comparative genomic hybridization (CGH) and cytogenetics provide complementary information to identify genetic abnormalities in AML.
Correlation of functional efflux and multidrug resistance (MDR1) expression in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR).
Acute promyelocytic leukemia associated wit t(11;17) is a discrete syndrome that fails to respond to retinoic acid.
An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the t(8;21) (q22;q22).
HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.
Identification and characterization of a previously unrecognized form of acute leukemia co-expressing myeloid and natural killer (NK) cell-associated antigens (CD56).
Clinical significance and functional analysis of the expression of the multidrug resistance gene (MDR1) in acute myeloid leukemia (AML).
Functional assessment of the multidrug (MDR1) resistance efflux pump in acute myeloid leukemia (AML): Identification of CD34-, CD33+, MRK16+ (MDR1+) cases lacking functional dye efflux.